Login to Your Account

Other News To Note

Thursday, June 30, 2011
Inovio Pharmaceuticals Inc., of Blue Bell, Pa., said its therapeutic DNA vaccine INO-5150 for prostate cancer-generated T-cell immune responses in monkeys. The company plans to start a Phase I trial in 2012.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription